Aptus Endosystems has completed $15 million in Series AA financing, which will be used advance the development of its Aptus EndoStapling system, part of the Aptus Endovascular abdominal aortic aneurysm (AAA) repair system, throughout Europe and the U.S.
According to the Sunnyvale, Calif.-based company, U.S. Venture Partners and Longitude Capital led the current round of funding. The financing was also based on obtaining a CE mark for the company's Aptus Endovascular AAA Repair system and the completion of the STAPLE-2 U.S. clinical trial, the company said.
The Aptus Endovascular AAA Repair system features an endograft and EndoStapling system that are used as an alternative to surgical repair and separate aneurysm exclusions and endograft fixation. Additionally, the company said that it is looking into the development of a thoracic aortic aneurysm (TAA) repair system.